Background
==========

A growing body of research suggests that elevated circulating levels of glucose and insulin accelerate risk factors for a wide range of pathological disorders \[[@B1]-[@B4]\]. Accordingly, interventions with low-risk dietary supplements that suppress glucose levels without raising insulin levels could offer significant long-term health benefits \[[@B5]\]. Animal studies and a single clinical trial previously reported that consumption of l-arabinose (LA), a poorly-absorbed, readily-available sweet-tasting pentose sugar, led to significant suppression of the circulating glucose and insulin after sucrose challenge \[[@B6]-[@B8]\]. This appears to be related to l-arabinose\'s ability to lessen the rapid absorption of sucrose typically found inmodern diets thereby preventing elevation of circulating levels of glucose and insulin \[[@B5]\] typically found in modern diets. Similarly, other animal and human studies have also reported suppression of circulating glucose levels without elevating insulin with the consumption of various forms of chromium (Cr) \[[@B9]-[@B13]\]. This appears to be related to chromium\'s ability to enhance insulin sensitivity. The purpose of this study was to examine the effects of a formula containing l- arabinose and trivalent chromium (LA-Cr) on circulating glucose and insulin responses to sucrose challenge.

Methods
=======

All subjects gave written informed consent in compliance with the Helsinki Declaration as approved by the researchers\' ethics committee.

Study 1, Phase 1
----------------

A total of 20 non-diabetic subjects were enrolled in this phase from a pool of subjects who had participated in previous studies and had demonstrated a high compliance with study protocols. Their relevant characteristics are set out in Table [1](#T1){ref-type="table"}. All 20 completed a DXA total body composition scan, the 50-item Quality of Life (QOL) inventory shown in Table [2](#T2){ref-type="table"} and the 43-chemistry blood test panel shown in Table [3](#T3){ref-type="table"}. Blood chemistries were drawn at a Quest service Center of the subject\'s choice <http://www.quest.com>.

###### 

Baseline demographics for Study 1, Phases 1 and 2, and Study 2

                         Study-1, Phase-1   Study-1, Phase-2   Study 2                   
  ---------------------- ------------------ ------------------ --------- ------- ------- -------
  Number Subjects        20                                    10                50      
                                                                                         
  Males                  6                                     3                 20      
                                                                                         
  Females                14                                    7                 30      
                                                                                         
  Blacks                 2                                     1                 11      
                                                                                         
  Hispanics              3                                     2                 12      
                                                                                         
  Whites                 4                                     7                 25      
                                                                                         
                         0                                     0                 2       
                                                                                         
                         Mean               SD                 Mean      SD      Mean    SD
                                                                                         
  Age                    53.8               11.3               53.7      11.8    40.2    14.8
                                                                                         
  Weight                 195.8              46.8               195.8     48.1    182.2   44.8
                                                                                         
  Height                 67.3               4.1                67.3      4.2     65.8    4.4
                                                                                         
  BMI                    29.9               6.0                30.2      6.1     29.6    6.0
                                                                                         
  Bone Mineral Density   1.189              0.102              1.189     0.104   1.202   0.092
                                                                                         
  \% Body Fat            42.4%              7.8%               42.4%     8.1%    38.9%   9.4%
                                                                                         
  Fat Mass               83.0               22.3               83.0      22.9    70.9    28.8
                                                                                         
  Fat-free Mass          112.8              35.6               112.8     36.6    111.3   27.4

###### 

Quality of Life Inventory

  ---- ------------------------------- ---- ------------------------------
  1    Headaches                       26   Irregular heartbeat
  2    Irritable bowel syndrome        27   Shortness of breath
  3    Arthritis                       28   Constipation
  4    Premenstrual syndrome           29   Stomach gas or indigestion
  5    Recurring sinus infections      30   Feeling weak
  6    Tension fatigue syndrome        31   Eating too rapidly
  7    Recurrent anxiety               32   Eating after being full
  8    Recurrent depression            33   Embarrassed about overeating
  9    Insomnia                        34   Depressed over eating habits
  10   Low self esteem                 35   Depressed about my weight
  11   Binge eating                    36   Difficult to stop eating
  12   Chronic tension                 37   Worrying about the future
  13   Lack of energy                  38   Unable to concentrate
  14   Food allergies                  39   Forgetfulness
  15   Feeling under stress            40   Bad temper or quick to anger
  16   Cancer                          41   Indigestion
  17   Prostate problems               42   Diabetes
  18   Overeating                      43   Vomiting
  19   Stomach pain                    44   Heartburn
  20   Back pain                       45   Esophageal reflux
  21   Pain in arms, legs, or joints   46   Control over my appetite
  22   Menstrual pain or problems      47   Ability to relax
  23   Chest pain                      48   Heart disease
  24   Dizziness                       49   Fibromyalgia
  25   Diarrhea                        50   Difficulty in falling asleep
  ---- ------------------------------- ---- ------------------------------

Subjects Rated Magnitude of Problems Occurring Over the last

30 Days Using a Scale of 0 = None, 1 = Minor, 2 = Major and 3 = Severe

###### 

The 43-Panel Blood Chemistry Test Completed by Subjects in Pilot Study, Phase-1

  LIPID PANEL              CBC (INCLUDES DIFF/PLT)
  ------------------------ -------------------------
  TRIGLYCERIDES            WHITE BLOOD CELL COUNT
                           
  CHOLESTEROL, TOTAL       RED BLOOD CELL COUNT
                           
  HDL CHOLESTEROL          HEMOBLOBIN
                           
  LDL CHOLESTEROL          HEMATOCRIT
                           
  CHOL/HDLC RATIO          MCV
                           
  METABOLIC PANEL          MCH
                           
  GLUCOSE                  MCHC
                           
  UREA NITROGEN (BUN)      RDW
                           
  CREATININE               PLATELET COUNT
                           
  BUN/CREATININE RATIO     ABSOLUTE NEUTROPHILS
                           
  SODIUM                   ABSOLUTE LYMPHOCYTES
                           
  POTASSIUM                ABSOLUTE MONOCYTES
                           
  CHLORIDE                 ABSOLUTE EOSINOPHILS
                           
  CARBO DIOXIDE            ABSOLUTE BASOPHILS
                           
  CALCIUM                  NEUTROPHILS
                           
  PROTEIN, TOTAL           LYMPHOCYTES
                           
  ALBUMIN                  MONOCYTES
                           
  GLOBULIN                 EOSINOPHILS
                           
  ALBUMIN/GLOBULIN RATIO   BASOPHILS
                           
  BILIRUBIN, TOTAL         OTHER MEASURES
                           
  ALKALINE PHOSPHATASE     CARDIO CRP
                           
  AST & ALT                TSH W/REFLEX TO FT4

On test day-1 (Control), after fasting for 10 hours, subjects completed a baseline \"finger-stick\" capillary blood sample, and consumed 70 grams of sugar dissolved in 150 grams of bottled water. Blood glucose levels were retested at 30, 45, 60 and 90 minutes. On test day 2 (Treatment), subjects followed the same procedure, but with a LA-Cr supplement containing 1,000 mg of l-arabinose and 200 mcg of a patented food-source chromium. All glucose measurements were obtained on-site using a glucometer (*ACCU-CHEK Aviva*meter, *ACCU-CHEK Multiclix*, and *Multiclix Pen*, Roche Diagnostics, Indianapolis IN).

For each subject and each timed test period, a change from baseline was obtained by subtracting the values for the corresponding baseline from the values of the four test periods. A glucose \"suppression score\" was obtained for each subject by subtracting the treatment change score from the control change score. The suppression scores were averaged over the 20 subjects and the changes from control scores to treatment scores were expressed as a percentage of control scores. Decreases were shown as negative percentages. The area under the curve (AUC) scores were obtained by using *KaleidaGraph*, *graphing and data analysis*, Version 3.6. The AUC scores for glucose treatment periods for each subject were compared to the control AUC scores for each subject using a paired, 2-tailed t-test. Significance was defined as *P*\< 0.05.

Study 1, Phase 2
----------------

Ten of the 20 subjects were randomly chosen and asked to consume a daily serving of LA-Cr for four weeks. Subjects provided daily tracking information on adverse effects. At the conclusion of each week, subjects completed the same Treatment sucrose challenge as described in Phase 1 and repeated the Blood, DXA, and QOL inventory at the end of the 4^th^week.

Study 2
-------

Fifty new non-diabetic subjects were recruited, and completed the same DXA and QOL inventory used in phase 2 of Study 1. In addition to glucose measurements, fasting insulin measurements were also obtained at baseline, 30 and 60 minutes from baseline with and without simultaneous consumption of the LA-Cr supplement at baseline. Insulin measurements were performed by Quest Laboratories, San Antonio, TX. The same procedures and instruments used in the pilot study were used to obtain glucose and insulin suppression scores. Significance was defined as *P*\< 0.05. All 50 subjects completed the glucose measurements. The phlebotomist was unable to draw blood from one subject and accordingly 49 subjects completed the insulin tests. To examine the relationship between the total glucose suppression or the total insulin suppression and baseline factors, each suppression score was compared with each baseline factor as follows: The data were ranked in order of suppression score and separated into quartiles, with Q1 representing the most suppression and Q4 representing the least suppression. An analysis of variance (ANOVA) was conducted across the 4 quartiles. Significance was defined as *P*\< 0.05.

Results
=======

The data for each of the groups and each of the time periods are shown in Table [4](#T4){ref-type="table"}. As shown in Table [5](#T5){ref-type="table"}, consuming La-Cr simultaneously with a 70 gram sucrose challenge (treatment) suppressed the glucose response in both Study 1 and 2 in all four time measurements as compared to control. These differences were statistically significant for all four time periods. Circulating insulin levels were also statistically lower at 60 minutes in the treatment group. Although not shown, weekly reductions in glucose were essentially the same in each of the four weeks as were found for these subjects in the first phase of Study 1. In addition, no significant changes were found in comparisons between baseline and ending blood chemistries and self-reported QOL scores.

###### 

Capillary Glucose and Venous Insulin Levels After a 70 g Sucrose Challenge With and Without Simultaneous Consumption of LA-Cr for the Pilot and Clinical Studies

  Pilot Study N = 20 (Glucose Measurements Only)                                                 
  -------------------------------------------------------------- ------- ------- ------- ------- -------
  Minutes from Baseline (glucose)                                :0      :30     :45     :60     :90
                                                                                                 
  Mean glucose levels in the control group (sugar only)          100.4   157.9   161.3   151.4   121.5
                                                                                                 
  Standard deviations of glucose in control group (sugar only)   16.1    23.8    18.5    24.7    17.0
                                                                                                 
  Mean glucose levels in the treatment group                     104.5   149.1   149.5   133.4   116.4
                                                                                                 
  Standard deviations of glucose levels in treatment group       12.0    15.9    16.8    20.7    13.7
                                                                                                 
                                                                                                 
                                                                                                 
  Clinical Study N = 50 (Glucose measurements)                                                   
                                                                                                 
  Minutes from Baseline (glucose)                                :0      :30     :45     :60     :90
                                                                                                 
  Mean glucose levels in the control group (sugar only)          97.2    150.3   151.4   141.8   120.5
                                                                                                 
  Standard deviations of glucose in control group (sugar only)   10.3    22.2    25.0    25.6    22.2
                                                                                                 
  Mean glucose levels in the treatment group                     99.9    142.8   140.0   133.5   116.9
                                                                                                 
  Standard deviations of glucose levels in treatment group       11.5    15.8    16.8    19.1    18.8
                                                                                                 
                                                                                                 
                                                                                                 
  Clinical Study N = 49 Insulin measurements)                                                    
                                                                                                 
  Minutes from Baseline (insulin)                                :0      :30     n/a     :60     n/a
                                                                                                 
  Mean insulin levels in the control group (sugar only)          4.4     32.3            32.2    
                                                                                                 
  Standard deviations of insulin in control group (sugar only)   3.9     24.7            19.9    
                                                                                                 
  Mean insulin levels in the treatment group                     4.4     29.0            24.4    
                                                                                                 
  Standard deviations of insulin scores in thetreatment group    3.9     20.6            16.5    

###### 

Changes from Baseline in Capillary Glucose and Venous Insulin Levels After a 70 g Sucrose Challenge With and Without Simultaneous Consumption of LA-Cr for Pilot Study (N = 20) and Clinical (N = 50).

  Pilot Study N = 20 (Glucose Only)                                                                
  -------------------------------------------- ------------ ------------ ------------ ------------ -------------
  **Minutes from Baseline**                    **30**       **45**       **60**       **90**       **AUC**
                                                                                                   
  \% Difference Between Treatment vs Control   -22.3%       -26.0%       -43.2%       -43.5%       -31.4%
                                                                                                   
  Significance Levels                          P \< 0.007   P \< 0.001   P \< 0.001   P \< 0.031   P \< 0.0001
                                                                                                   
                                                                                                   
                                                                                                   
  **Clinical Study N = 50 (Glucose Only)**                                                         
                                                                                                   
  **Minutes from Baseline (Glucose)**          **30**       **45**       **60**       **90**       **AUC**
                                                                                                   
  \% Difference Between Treatment vs Control   -19.1%       -26.1%       -24.8%       -27.1%       -18.4%
                                                                                                   
  Significance Levels                          P \< 0.01    P \< 0.001   P \< 0.01    P \< 0.05    P \< 0.0001
                                                                                                   
  **Clinical Study N = 49 (Insulin Only)**                                                         
                                                                                                   
  **Minutes from Baseline (Insulin)**          **30**                    **60**                    **AUC**
                                                                                                   
  \% Difference Between Treatment vs Control   -11.9%                    -28.3%                    -28.3%
                                                                                                   
  Significance Levels                          NS                        P \< 0.001                P \< 0.01

*P*values are from repeated measures t-test and Ar

To further examine the association between suppression scores and baseline measures, glucose and insulin suppression scores were divided into four equal quartiles. An ANOVA revealed that there were no statistically significant relationships between glucose suppression scores and baseline measures of glucose, insulin, age, gender, ethnicity, scale weight, height, bone mineral density, total body fat, total body lean, and body mass index. However, there was a significant association between glucose suppression scores and % body fat (*P*= 0.038). A further comparison of the quartiles of glucose suppression scores and % body fat revealed that the greater the suppression score, the lower the % body fat (Q4 = 42.5%, Q3 = 40.8%, Q2 = 40.0%, Q1 = 32.5%). A Student t-test between the highest (n = 12) and lowest (n = 12) glucose suppression quartiles was also significant (*P*= 0.025).

Discussion
==========

This study compared the acute effects of the simultaneous ingestion of a combined l-arabinose and trivalent chromium formulation (LA-Cr) after a 70 gram oral challenge of sucrose. Sucrose absorption was estimated by the appearance of increased levels of circulating glucose after the sucrose challenge \[[@B6]\]. Data from two separate studies found an 18% to 31% reduction in glucose when taking LA-Cr supplement compared to ingesting the sucrose alone. In the second study, we also found a 28% reduction in circulating insulin concentrations 60 minutes after taking the formulation. With regard to safety, other than some discomfort with the capillary measurements, no adverse effects were reported. Nor were any adverse effects reported among the 10 subjects who consumed the LA-Cr daily for the 4-week study period.

When the effects of the LA-Cr were measured weekly with the acute oral sucrose challenge, the glucose-lowering response of the combination remained over the 28-day period. Additionally, there were no significant differences between baseline and ending values on any of the 43 blood chemistries, DXA body composition measures, or the self-reported Quality of Life Inventory after using the LA-Cr daily for 28 days.

We devised our protocol with the thought that we were essentially examining the l-arabinose in the formula. Findings similar to ours have been reported in a well-controlled rat model, i.e., l-arabinose works quickly when taken prior to a sucrose challenge and continues to work effectively over a sub chronic period of time that may provide insights into the mechanisms of action. The data support the hypothesis that l-arabinose worked by blocking sucrose absorption \[[@B6],[@B13]\]. In rats, l-arabinose did not influence circulating glucose levels when no sucrose, but rather saline, was given. Under these circumstances, it did not lower glucose via enhancing uptake or metabolism of glucose. Further, l-arabinose did not affect glucose appearance when glucose replaced sucrose as the challenging sugar. Finally, *in vitro*studies have shown that l-arabinose blocks sucrase in an uncompetitive manner \[[@B14]\].

This was unlike effects with chromium that influence circulating glucose levels through an ability to enhance insulin sensitivity and its removal from the circulation. While chromium could have influenced the results of our sub-chronic study, it is unlikely to have done so in the acute studies since chromium does not work acutely after initial intake \[[@B8]-[@B12]\]. Our studies examined the product with both ingredients without partitioning the individual or interactive effects of chromium and l-arabinose.

To explore individualized reactions, we examined the association between suppression scores and baseline measures by sub-grouping glucose and insulin suppression scores into four equal quartiles. An ANOVA revealed that there were no statistically significant relationships between glucose suppression scores and baseline measures of glucose, insulin, age, gender, ethnicity, scale weight, height, bone mineral density, total body fat, total body lean, and body mass index. However, there was a significant association between glucose suppression scores and % body fat (*P*= 0.038). A further comparison of the quartiles of glucose suppression scores and % body fat revealed that the greater the suppression score, the lower the % body fat (Q4 = 32.5%, Q3 = 40.8%, Q2 = 40.8%, Q1 = 42.5%). A Student t-test between the highest (n = 12) and lowest (n = 12) glucose suppression quartiles was also significant (*P*= 0.025). This could suggest that the higher the subject\'s % fat, the more LA-Cr may be required to obtain the same glucose suppression results.

An ANOVA of the insulin suppression score quartiles failed to reach statistical significance on any of the baseline measures, including % body fat. However, a t-test between the highest and lowest age quartiles (Q4 = 33.9 yrs, Q3 = 40.1 yrs, Q2 = 40.6 yrs, Q1 = 46.5 yrs) revealed a significant relationship between age and insulin suppression suggesting the insulin suppression effect may be greatest in younger people. However, the irregular pattern of Q2-Q4 calls this interpretation into question, suggesting it may be a statistical artifact as a function of the multiple ANOVA analyses conducted.

The data from these two separate studies reveal that a formula containing l-arabinose and chromium (LA-Cr) can facilitate a consistent suppression of both circulating glucose and insulin without adverse side effects. The replication of the suppressive effect observed in the two sequential studies increases the confidence of the formula\'s efficacy. Furthermore, the percentage of subjects for whom the supplement had at least some suppressive effect, 78% for glucose and 70% for insulin, is particularly noteworthy since we had little control over how many subjects actually fasted for the required 10 hours prior to being tested.

There is a widespread belief that we are undergoing a global \"epidemic\" of obesity and diabetes \[[@B14]-[@B16]\]. Some studies have suggested that an important contributing factor is the greater intake of rapidly absorbed or simple carbohydrates, particularly sugar \[[@B17]-[@B19]\]. At least one study \[[@B19]\] suggests that rapidly absorbed carbohydrates are more harmful than those that are more slowly absorbed, perhaps due to the difference in their effects on the glucose-insulin system. The data derived from this study suggest that it may be feasible to suppress the harmful effects of glucose and insulin associated with intake of rapid carbohydrates with a low- or no-risk dietary supplement. Since even small reductions of circulating glucose and insulin can have significant health benefits, this study suggests that longer-term and dose-related studies need to be conducted.
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